Juvenile idiopathic arthritis: Management and therapeutic options

Therapeutic Advances in Musculoskeletal Disease

Volumn 4, Issue 2, 2012, Pages 99-110

  Ruth, Natasha M ^a   Passo, Murray H ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

disease modifying agents; interleukin 1 blockade; interleukin 6 blockade; juvenile idiopathic arthritis; non steroidal anti inflammatory drugs; selective B cell blockade; selective costimulation modulators; tumor necrosis factor alpha inhibitors

Indexed keywords

ABATACEPT; ADALIMUMAB; AZATHIOPRINE; CANAKINUMAB; CORTICOSTEROID DERIVATIVE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FOLIC ACID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; LEFLUNOMIDE; MERCAPTOPURINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TRIAMCINOLONE ACETONIDE; TRIAMCINOLONE HEXACETONIDE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANALGESIA; AUTOIMMUNE DISEASE; AVERSIVE BEHAVIOR; B LYMPHOCYTE; BACTERIAL INFECTION; CARDIOPULMONARY ARREST; DEPRESSION; DIARRHEA; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ENTERITIS; FLU LIKE SYNDROME; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION PROFILING; HASHIMOTO DISEASE; HERPES ZOSTER; HISTOPLASMOSIS; HODGKIN DISEASE; HUMAN; INFECTION; INFUSION RELATED REACTION; INJECTION SITE REACTION; JOINT CONTRACTURE; JUVENILE RHEUMATOID ARTHRITIS; LEUKEMIA; LOADING DRUG DOSE; LOW DRUG DOSE; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MOUTH ULCER; MYCOBACTERIOSIS; MYCOSIS; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PSORIASIS; RELAPSE; REMISSION; REVIEW; SIDE EFFECT; SOLID TUMOR; T CELL LYMPHOMA; TREATMENT DURATION; URTICARIA; UVEITIS;

EID: 84868653509     PISSN: 1759720X     EISSN: 17597218     Source Type: Journal    
DOI: 10.1177/1759720X11413630     Document Type: Review

References (86)

1. Albers H.M. Wessels J.A. van der Straaten R.J. Brinkman D.M. Suijlekom-Smit L.W. Kamphuis S.S. et al (2009) Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis. Arthritis Rheum 61: 46–51.
2. Barnes M.G. Grom A.A. Thompson S.D. Ilowite N.T. Olson J.C. Sherry D.D. et al (2009) Gene Expression Signatures in new onset untreated juvenile idiopathic arthritis. Arthritis Rheum 60: 2101–2112.
3. Berger J.R. Houff S.A. Major E.O. (2009) Monoclonal antibodies and progressive multifocal leukoencephalopathy. m Abs 1: 583–589.
4. Bernatsky S. Rosenberg A.M. Oen K.G. Duffy C.M. Ramsey-Goldman R. Labrecque J. et al (2011) Malignancies in juvenile idiopathic arthritis: a preliminary report. J Rheumatol 38: 760–763.
5. Beukelman T. Guevara J.P. Albert D.A. (2008) Optimal treatment of knee monarthritis in juvenile idiopathic arthritis: a decision analysis. Arthritis Rheum 59: 1580–1588.
6. Beukelman T. Guevara J.P. Albert D.A. Sherry D.D. Burnham J.M. (2007) Variation in the initial treatment of knee monoarthritis in juvenile idiopathic arthritis: a survey of pediatric rheumatologists in the United States and Canada. J Rheumatol 34: 1918–1924.
7. Beukelman T. Patkar N.M. Saag K.G. Tolleson-Rinehart S. Cron R.Q. Dewitt E.M. et al (2011) 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res 63: 465–482.
8. Bhettay E. (1986) Double-blind study of sulindac and aspirin in juvenile chronic arthritis. Suid-Afrikaanse tydskrif vir geneeskunde 70: 724–726.
9. Breda L. Del Torto M. de Sanctis S. Chiarelli F. (2011) Biologics in children's autoimmune disorders: efficacy and safety. Eur J Pediatrics 170: 157–167.
10. Breit W. Frosch M. Meyer U. Heinecke A. Ganser G. (2000) A subgroup-specific evaluation of the efficacy of intraarticular triamcinolone hexacetonide in juvenile chronic arthritis. J Rheumatol 27: 2696–2702.
11. Center for Drug Evaluation and Research (1999) Guidance for Industry: clinical development programs for drugs, devices, and biological products for the treatment of rheumatoid arthritis. US Department of Health and Human Services, Food and Drug Administration, available at: http://wwwfdagov/cber/gdllns/rheumclnpdf (February).
12. Cucchiara S. Morley-Fletcher A. (2007) “New drugs: kids come first”: children should be included in trials of new biological treatments. Inflamm Bowel Dis 13: 1165–1169; discussion 1176-1177.
13. Damasio M.B. Malattia C. Martini A. Toma P. (2010) Synovial and inflammatory diseases in childhood: role of new imaging modalities in the assessment of patients with juvenile idiopathic arthritis. Pediatric Radiol 40: 985–998.
14. Danila M.I. Hughes L.B. Bridges S.L. (2008) Pharmacogenetics of etanercept in rheumatoid arthritis. Pharmacogenomics 9: 1011–1015.
15. de Benedetti F. Martini A. (1998) Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease?. J Rheumatol 25: 203–207.
16. Diak P. Siegel J. La Grenade L. Choi L. Lemery S. McMahon A. (2010) Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum 62: 2517–2524.
17. Eberhard B.A. Sison M.C. Gottlieb B.S. Ilowite N.T. (2004) Comparison of the intraarticular effectiveness of triamcinolone hexacetonide and triamcinolone acetonide in treatment of juvenile rheumatoid arthritis. J Rheumatol 31: 2507–2512.
18. El-Hallak M. Binstadt B.A. Leichtner A.M. Bennett C.M. Neufeld E.J. Fuhlbrigge R.C. et al (2007) Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases. J Pediatrics 150: 376–382.
19. Fall N. Barnes M. Thornton S. Luyrink L. Olson J. Ilowite N.T. et al (2007) Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. Arthritis Rheum 56: 3793–3804.
20. Foeldvari I. Wierk A. (2010) Effectiveness of leflunomide in patients with juvenile idiopathic arthritis in clinical practice. J Rheumatol 37: 1763–1767.
21. Foell D. Wulffraat N. Wedderburn L.R. Wittkowski H. Frosch M. Gerss J. et al (2010) Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 303: 1266–1273.
22. Frosch M. Roth J. (2008) New insights in systemic juvenile idiopathic arthritis–from pathophysiology to treatment. Rheumatology 47: 121–125.
23. Frosch M. Strey A. Vogl T. Wulffraat N.M. Kuis W. Sunderkotter C. et al (2000) Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum 43: 628–637.
24. Giannini E.H. Brewer E.J. Kuzmina N. Shaikov A. Maximov A. Vorontsov I. et al (1992) Methotrexate in resistant juvenile rheumatoid arthritis. Results of the USA.–USS.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. N Engl J Med 326: 1043–1049.
25. Giannini E.H. Brewer E.J. Miller M.L. Gibbas D. Passo M.H. Hoyeraal H.M. et al (1990) Ibuprofen suspension in the treatment of juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. J Pediatrics 117: 645–652.
26. Giannini E.H. Ruperto N. Ravelli A. Lovell D.J. Felson D.T. Martini A. (1997) Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 40: 1202–1209.
27. Haines K.A. (2007) Juvenile idiopathic arthritis: therapies in the 21st century. Bull NYU Hospital Joint Dis 65: 205–211.
28. Halle F. Prieur A.M. (1991) Evaluation of methotrexate in the treatment of juvenile chronic arthritis according to the subtype. Clin Exp Rheumatol 9: 297–302.
29. Harel L. Wagner-Weiner L. Poznanski A.K. Spencer C.H. Ekwo E. Magilavy D.B. (1993) Effects of methotrexate on radiologic progression in juvenile rheumatoid arthritis. Arthritis Rheum 36: 1370–1374.
30. Hashkes P.J. Laxer R.M. (2005) Medical treatment of juvenile idiopathic arthritis. JAMA 294: 1671–1684.
31. Hashkes P.J. Uziel Y. Laxer R.M. (2010) The safety profile of biologic therapies for juvenile idiopathic arthritis. Nat Rev Rheumatol 6: 561–571.
32. Hayward K. Wallace C.A. (2009) Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis. Arthritis Res Therapy 11: 216.
33. Hoffman H.M. Throne M.L. Amar N.J. Sebai M. Kivitz A.J. Kavanaugh A. et al (2008) Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 58: 2443–2452.
34. Hunt P.G. Rose C.D. McIlvain-Simpson G. Tejani S. (1997) The effects of daily intake of folic acid on the efficacy of methotrexate therapy in children with juvenile rheumatoid arthritis. A controlled study. J Rheumatol 24: 2230–2232.
35. Ilowite N. Porras O. Reiff A. Rudge S. Punaro M. Martin A. et al (2009) Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol 28: 129–137.
36. Ilowite N.T. (2002) Current treatment of juvenile rheumatoid arthritis. Pediatrics 109: 109–115.
37. Isaacs J.D. (2009) Antibody engineering to develop new antirheumatic therapies. Arthritis Res Therapy 11: 225.
38. Jansson A.F. Sengler C. Kuemmerle-Deschner J. Gruhn B. Kranz A.B. Lehmann H. et al (2011) B cell depletion for autoimmune diseases in paediatric patients. Clin Rheumatol 30: 87–97.
39. Jarvis J.N. Frank M.B. (2010) Functional genomics and rheumatoid arthritis: where have we been and where should we go?. Genome Med 2: 44.
40. Kanakoudi-Tsakalidou F. Tzimouli V. Pratsidou-Gertsi P. Chronopoulou E. Trachana M. (2008) The significance of persistent newly developed autoantibodies in JIA patients under long-term anti-TNF treatment. Cytokine 42: 293–297.
41. Krumrey-Langkammerer M. Hafner R. (2001) Evaluation of the ILAR criteria for juvenile idiopathic arthritis. J Rheumatol 28: 2544–2547.
42. Lachmann H.J. Kone-Paut I. Kuemmerle-Deschner J.B. Leslie K.S. Hachulla E. Quartier P. et al (2009) Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 360: 2416–2425.
43. Lovell D. Ruperto N. Jung L. Reiff A.O. Nemcova D. Jarosova K. et al (2006) Long-term efficacy and safety of adalimumab in children with juvenile rheumatoid arthritis: 48-week results. Arthritis Rheum 54(Suppl.): s303.
44. Lovell D.J. Giannini E.H. Reiff A. Cawkwell G.D. Silverman E.D. Nocton J.J. et al (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 342: 763–769.
45. Lovell D.J. Reiffe A. Jones O.Y. Schneider R. Nocton J. Stein L.D. et al. (2006) Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 54: 1987–1994.
46. Lovell D.J. Reiff A. Ilowite N.T. Wallace C.A. Chon Y. Lin S.L. et al (2008 a) Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 58: 1496–1504.
47. Lovell D.J. Ruperto N. Goodman S. Reiff A. Jung L. Jarosova K. et al (2008 b) Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 359: 810–820.
48. Marti P. Molinari L. Bolt I.B. Seger R. Saurenmann R.K. (2008) Factors influencing the efficacy of intra-articular steroid injections in patients with juvenile idiopathic arthritis. Eur J Pediatrics 167: 425–430.
49. McCann L.J. Woo P. (2007) Biologic therapies in juvenile idiopathic arthritis: why and for whom?. Acta Reumatologica Portuguesa 32: 15–26.
50. Minden K. (2009) Adult outcomes of patients with juvenile idiopathic arthritis. Hormone Res 72(Suppl. 1): 20–25.
51. Nigrovic P.A. Mannion M. Prince F.H. Zeft A. Rabinovich C.E. van Rossum M.A. et al (2011) Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 63: 545–555.
52. Ogilvie E.M. Khan A. Hubank M. Kellam P. Woo P. (2007) Specific gene expression profiles in systemic juvenile idiopathic arthritis. Arthritis Rheum 56: 1954–1965.
53. Onel K.B. Onel K. (2010) Anti-tumor necrosis factor therapy and cancer risk in patients with autoimmune disorders. Arthritis Care Res 62: 1024–1028.
54. Padeh S. Passwell J.H. (1998) Intraarticular corticosteroid injection in the management of children with chronic arthritis. Arthritis Rheum 41: 1210–1214.
55. Pascual V. Allantaz F. Arce E. Punaro M. Banchereau J. (2005) Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 201: 1479–1486.
56. Prey S. Paul C. (2009) Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review. Br J Dermatol 160: 622–628.
57. Quartier P. Allantaz F. Cimaz R. Pillet P. Messiaen C. Bardin C. et al (2011) A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 70: 747–754.
58. Ramanan A.V. Grom A.A. (2005) Does systemic-onset juvenile idiopathic arthritis belong under juvenile idiopathic arthritis?. Rheumatology 44: 1350–1353.
59. Ravelli A. Manzoni S.M. Viola S. Pistorio A. Ruperto N. Martini A. (2001) Factors affecting the efficacy of intraarticular corticosteroid injection of knees in juvenile idiopathic arthritis. J Rheumatol 28: 2100–2102.
60. Ravelli A. Migliavacca D. Viola S. Ruperto N. Pistorio A. Martini A. (1999 a) Efficacy of folinic acid in reducing methotrexate toxicity in juvenile idiopathic arthritis. Clin Exp Rheumatol 17: 625–627.
61. Ravelli A. Ramenghi B. Di Fuccia G. Ruperto N. Zonta L. Martini A. (1994) Factors associated with response to methotrexate in systemic-onset juvenile chronic arthritis. Acta Paediatrica 83: 428–432.
62. Ravelli A. Viola S. Migliavacca D. Ruperto N. Pistorio A. Martini A. (1999 b) The extended oligoarticular subtype is the best predictor of methotrexate efficacy in juvenile idiopathic arthritis. J Pediatrics 135: 316–320.
63. Ravelli A. Viola S. Ramenghi B. Beluffi G. Zonta L.A. Martini A. (1998) Radiologic progression in patients with juvenile chronic arthritis treated with methotrexate. J Pediatrics 133: 262–265.
64. Rubbert-Roth A. Finckh A. (2009) Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Therapy 11(Suppl. 1): S1.
65. Ruperto N. Lovell D.J. Cuttica R. Wilkinson N. Woo P. Espada G. et al (2007) A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 56: 3096–3106.
66. Ruperto N. Lovell D.J. Cuttica R. Woo P. Meiorin S. Wouters C. et al (2010) Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis 69: 718–722.
67. Ruperto N. Lovell D.J. Quartier P. Paz E. Rubio-Perez N. Silva C.A. et al (2008) Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 372: 383–391.
68. Ruperto N. Murray K.J. Gerloni V. Wulffraat N. de Oliveira S.K. Falcini F. et al (2004) A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 50: 2191–2201.
69. Sharma R. Sharma C.L. Mahajan A. (2008) Biological agents targeting beyond TNF-alpha. Indian J Crit Care Med 12: 181–189.
70. Shirota Y. Illei G.G. Nikolov N.P. (2008) Biologic treatments for systemic rheumatic diseases. Oral Dis 14: 206–216.
71. Silverman E. Mouy R. Spiegel L. Jung L.K. Saurenmann R.K. Lahdenne P. et al (2005) Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med 352: 1655–1666.
72. Smith J.A. Kauffman C.A. (2009) Endemic fungal infections in patients receiving tumour necrosis factor-alpha inhibitor therapy. Drugs 69: 1403–1415.
73. Smith J.A. Thompson D.J. Whitcup S.M. Suhler E. Clarke G. Smith S. et al (2005) A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 53: 18–23.
74. Tynjala P. Kotaniemi K. Lindahl P. Latva K. Aalto K. Honkanen V. et al (2008) Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology 47: 339–344.
75. Unsal E. Makay B. (2008) Intraarticular triamcinolone in juvenile idiopathic arthritis. Indian Pediatrics 45: 995–997.
76. van der Meer A. Wulffraat N.M. Prakken B.J. Gijsbers B. Rademaker C.M. Sinnema G. (2007) Psychological side effects of MTX treatment in juvenile idiopathic arthritis: a pilot study. Clin Exp Rheumatol 25: 480–485.
77. van Rossum M.A. Fiselier T.J. Franssen M.J. Zwinderman A.H. ten Cate R. van Suijlekom-Smit L.W. et al (1998) Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum 41: 808–816.
78. van Rossum M.A. van Soesbergen R.M. Boers M. Zwinderman A.H. Fiselier T.J. Franssen M.J. et al (2007) Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment. Ann Rheum Dis 66: 1518–1524.
79. Vastert S.J. Kuis W. Grom A.A. (2009) Systemic JIA: new developments in the understanding of the pathophysiology and therapy. Best Practice Res Clin Rheumatol 23: 655–664.
80. Vazquez-Cobian L.B. Flynn T. Lehman T.J. (2006) Adalimumab therapy for childhood uveitis. J Pediatrics 149: 572–575.
81. Wallace C.A. Ruperto N. Giannini E. (2004) Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 31: 2290–2294.
82. Wittkowski H. Frosch M. Wulffraat N. Goldbach-Mansky R. Kallinich T. Kuemmerle-Deschner J. et al (2008) S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis Rheum 58: 3924–3931.
83. Woo P. Southwood T.R. Prieur A.M. Dore C.J. Grainger J. David J. et al (2000) Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 43: 1849–1857.
84. Yokota S. Imagawa T. Mori M. Miyamae T. Aihara Y. Takei S. et al (2008) Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 371: 998–1006.
85. Zulian F. Balzarin M. Falcini F. Martini G. Alessio M. Cimaz R. et al (2010) Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res 62: 821–825.
86. Zulian F. Martini G. Gobber D. Plebani M. Zacchello F. Manners P. (2004) Triamcinolone acetonide and hexacetonide intra-articular treatment of symmetrical joints in juvenile idiopathic arthritis: a double-blind trial. Rheumatology 43: 1288–1291.